Bliss GVS Pharma Limited has informed the Exchange about Communication to Shareholders - Intimation of Tax Deduction on Dividend
BLISSGVS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bliss GVS Pharma has informed shareholders that the Board, at its May 12, 2025 meeting, recommended a final dividend of Re. 0.50 per equity share (face value Re. 1) for FY 2024-25, pending approval at the 40th AGM on July 31, 2025. The record date for eligibility has been fixed as July 24, 2025. Since dividend distribution tax was abolished by the Finance Act 2020, the company will deduct tax at source (TDS) at the time of payment — 10% for resident shareholders with valid PAN, 20% for those without/invalid PAN, and 20% (plus surcharge/cess) for non-residents. No TDS will apply if total dividend to a resident individual in FY 2025-26 does not exceed Rs. 10,000, or if eligible shareholders submit Form 15G/15H before the July 24, 2025 cut-off. Shareholders are urged to update KYC, PAN, and bank details to ensure smooth credit.
Shareholders will receive a modest Re. 0.50 per share dividend net of TDS; small retail investors (under Rs. 10,000 annual dividend) and senior citizens (with Form 15H) can avoid TDS, but failing to submit documents by July 24, 2025 will result in higher 20% deduction. This is a routine compliance filing with no material impact on stock price.